<DOC>
	<DOCNO>NCT00678535</DOCNO>
	<brief_summary>The primary objective study demonstrate addition cetuximab 1st-line treatment capecitabine ( Xeloda , X ) cisplatin ( P ) [ XP ] chemotherapy regimen clinically relevant benefit subject advance gastric adenocarcinoma include gastroesophageal junction ( GEJ ) adenocarcinoma , term progression free survival ( PFS ) . Secondary objective assess cetuximab plus XP versus XP alone respect overall survival , overall tumor response , quality life ( QoL ) safety .</brief_summary>
	<brief_title>Erbitux Combination With Xeloda Cisplatin Advanced Esophago-gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent studyrelated activity carry Age great equal ( &gt; = ) 18 year Histologically confirm adenocarcinoma stomach gastroesophageal junction ( Adenocarcinoma gastroesophageal junction [ AEG ] Types IIII accord Siewert classification ) Archived tumor material sample least subsequent standardize Epidermal Growth Factor Receptor ( EGFR ) expression assessment Unresectable advance ( M0 ) unresectable metastatic ( M1 ) disease At least one radiographically document measurable lesion previously nonirradiated area accord response evaluation criterion solid tumor ( RECIST ) . The primary tumor site consider nonmeasurable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Estimated life expectancy great ( &gt; ) 12 week Medically accept contraception ( risk conception exists ) Glomerular filtration rate ( GFR ) &gt; = 60 milliliter per minute ( mL/min ) The GFR base CockcroftGault formula creatinine clearance Aspartateaminotransferase ( ASAT ) less equal ( = &lt; ) 2.5 * upper limit normal ( ULN ) alanineaminotransferase ( ALAT ) = &lt; 2.5 *ULN Bilirubin = &lt; 3 * ULN Absolute neutrophil count ( ANC ) &gt; = 1.5 * 10^9 per liter Platelets &gt; = 100 * 10^9 per liter Hemoglobin &gt; =10 gram per deciliter ( g/dL ) ( without transfusion ) Sodium potassium within normal limit = &lt; 10 percent ( supplementation permit ) Prior chemotherapy , however , previous ( neo ) adjuvant ( radio ) chemotherapy allow finish &gt; 1 year prior start study treatment 300 mg/m^2 cisplatin administer Prior treatment antibody molecule target EGFR and/or Vascular Endothelial Growth Factor Receptor ( VEGFR ) relate signal pathway Brain metastasis and/or leptomeningeal disease ( know suspect ) Radiotherapy ( except localize radiotherapy pain relief ) , major surgery investigational drug within 30 day start study treatment Concurrent chronic systemic immune hormone therapy indicate study protocol ( except physiologic replacement ) Clinically relevant coronary artery disease ( New York Heart Association [ NYHA ] functional angina classification III/IV ) , congestive heart failure ( NYHA III/IV ) , clinically relevant cardiomyopathy , history myocardial infarction 12 month study Screening , high risk uncontrolled arrhythmia Active Hepatitis B C Chronic diarrhea short bowel syndrome Presence contraindication treatment cetuximab , capecitabine cisplatin include : Known hypersensitivity capecitabine , fluorouracil , cisplatin , cetuximab excipients drug Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Current treatment sorivudine chemically related analogue , brivudine Symptomatic peripheral neuropathy National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Grade &gt; = 2 and/or ototoxicity NCI CTCAE Grade &gt; = 2 , except due trauma mechanical impairment due tumor mass Pregnancy lactation period Concurrent treatment nonpermitted drug Treatment another clinical study within 30 day prior study screen Previous malignancy gastric cancer within 5 year prior study screen , except basal cell cancer skin preinvasive cancer cervix Medical psychological condition would permit subject complete study sign inform consent Legal incapacity limit legal capacity Significant disease , Investigator 's opinion , would exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>1st line treatment Gastric Cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Progression-free survival</keyword>
</DOC>